Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2952W HIGH $10.98
Volume
89.67 K
Value Traded
26.41 K
Short % Float
1.59%
Days to Cover
1.0
-17.14%Week
-56.16%1 Month
+333.76%3 Month
+370.89%6 Month
-86.01%5 Year
-86.01%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.68 M
EPS (TTM)
-10.84
P/E Ratio
-
Ent. Value
678.72 K
Total Shares
829.40 K
Float Shares
820.00 K
Insiders
21.36%
Institutions
10.39%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NXL Catalyst Timeline
Dated clinical, regulatory and corporate events for Nexalin Technology, Inc.
Past FDA Catalysts and PDUFA Decisions
How NXL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Nexalin Technology, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NXL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Nexalin DIFS™ | insomnia and anxiety | 2026-06-23 | significant improvement in sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI), observed both at the end of treatment and at follow-up, with large effect sizesRead More | Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ PlatformRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Elson Marilyn10% Owner | Sell | -23,150 112,850 held | $0.02 | 09/10/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in NXL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NXL for Q2 2026. | ||||
NXL Institutional Ownership Trends
NXL Short Interest
Shares sold short, counted twice a month.
1.59%
Short % of Float
of tradable shares sold short
13.1K
Shares Sold Short
+4.6% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
14.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NXL ranks across every disease it competes in
Competitive Position is a premium feature
See how NXL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNXL News
NXLNexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
Nexalin Technology has confirmed compliance with Nasdaq's minimum bid price requirement after its stock price exceeded $1.00 for 21 consecutive days. This follows a decision by the Nasdaq Hearings Panel to grant the company continued listing. Nexalin is focused on advancing its clinical programs and has secured a distribution agreement in South America, but it must still meet additional financial requirements by early 2027.
Read more →NXL▲ +76.4%on this news
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
Nexalin Technology has signed an exclusive distribution agreement with Inovanexa Medical Technologies for its Nexalin Sync device across Brazil and six other South American countries. The agreement establishes a 10-year commercial framework and includes an initial order for 100 devices, with a clinical pilot program to launch within 90 days. This strategic move aims to transition Nexalin into a revenue-generating company while addressing mental health issues in the region.
Read more →NXLNexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy
Nexalin Technology has appointed Robert DiTota as Senior Strategic Advisor to guide its commercialization strategy for the DIFS™ platform. This move follows the company's successful clinical and regulatory groundwork, including approvals in China, Brazil, Oman, and Israel. Nexalin aims to leverage DiTota's extensive experience in neuromodulation to develop distribution relationships and market strategies as it transitions from clinical development to commercial sales.
Read more →NXL▼ -13.4%on this news
Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer’s Pilot Study
Nexalin Technology announced a secondary analysis of its clinical trial data for Alzheimer's patients, revealing significant improvements in memory, comprehension, and language function. The analysis, which focused on the ADAS-Cog scale, indicated that half of the participants showed clinically meaningful cognitive enhancements. These insights are expected to inform the design of a planned U.S. pilot study.
Read more →NXL▼ -13.6%on this news
Nexalin Technology Announces Reverse Stock Split
Nexalin Technology, Inc. has announced a 1-for-30 reverse stock split to comply with Nasdaq's bid-price rule. The split will take effect on August 28, 2026, with trading adjusted accordingly on August 31, 2026. The company aims to maintain its listing on Nasdaq while continuing to develop its innovative neurostimulation products.
Read more →NXLNexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
Nexalin Technology announced that Dr. Victor Fontenelle Bastos de Lima received the Young Researcher Award at BRAIN 2026 for his research on the DIFS™ platform. The study demonstrated significant improvements in sleep quality among patients with insomnia and anxiety. This recognition enhances Nexalin's credibility as it prepares for a product launch in Brazil.
Read more →NXLNexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
Nexalin Technology has announced the acceptance of two clinical abstracts for presentation at the 2026 NYC Neuromodulation Conference. The abstracts highlight positive preliminary results from their DIFS™ treatment platform, showing significant improvements in anxiety, depression, insomnia, and quality of life. The data demonstrate a high response rate and sustained benefits, reinforcing the platform's scientific viability.
Read more →NXLNexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
Nexalin Technology announced positive results from a clinical trial in Brazil, demonstrating a 77.8% anxiety response rate and significant improvements in depression and insomnia. The trial, which involved 20 sessions of neurostimulation, showed durable benefits maintained at an 8-week follow-up. The results support Nexalin's non-invasive treatment approach and its plans for a product launch in Brazil.
Read more →NXLNexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
Nexalin Technology has announced the issuance of a U.S. patent for its dynamic frequency stimulation method, aimed at treating anxiety, depression, and insomnia. This patent will provide intellectual property protection until 2042, reinforcing Nexalin's competitive edge in non-invasive neurostimulation. The company believes this technology can significantly improve mental health treatment options and is central to its strategic initiatives.
Read more →NXL▲ +19.1%on this news· ran to +67% by day 3
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
Nexalin Technology, Inc. has secured a significant legislative provision from the U.S. House Appropriations Committee that directs the Department of Veterans Affairs (VA) to support research into non-invasive deep brain neurostimulation technologies for veterans suffering from treatment-resistant traumatic brain injury (TBI). This favorable report language comes as part of the Fiscal Year 2027 Appropriations bill, which has passed the House with overwhelming support. The inclusion indicates a growing recognition of the potential benefits of Nexalin's DIFS™ technology and aims to distinguish it from traditional stimulation methods.
Read more →NXLNexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
Nexalin Technology, Inc. has acquired PONM, Inc., enhancing its HALO™ Clarity program with AI-integrated digital health capabilities. This acquisition allows Nexalin to manage remote patient monitoring and clinical data workflows more effectively. The platform is already in use at UCSD and will support Nexalin's upcoming pivotal trial for insomnia treatment, expected to begin in Q2 2026.
Read more →NXLNexalin Acquires AI-Integrated Digital Health Platform Behind HALO Clarity and Nexalin NeuroCare Ahead of Planned FDA Pivotal Trial
Nexalin Technology, Inc. has completed its acquisition of PONM, Inc., a digital health platform that supports the HALO Clarity program and Nexalin NeuroCare virtual clinic. This acquisition grants Nexalin control over essential AI-integrated technologies for remote patient monitoring and clinical data capture. The technology, already deployed at UCSD, is expected to enhance treatment oversight for an upcoming pivotal trial for HALO Clarity. Nexalin's strategy aims to leverage the integrated platform for efficient regulatory submission and commercialization of its at-home therapy solutions.
Read more →NXL▼ -8.6%on this news
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
Nexalin Technology, Inc. announced the publication of a peer-reviewed study demonstrating significant clinical improvement in chronic insomnia patients treated with its DIFS™ technology. The study reported a notable reduction in Pittsburgh Sleep Quality Index scores for the active treatment group compared to the sham group. Neuroimaging data provided mechanistic insights into how the treatment modulates brain networks associated with sleep quality.
Read more →NXL▲ +7.7%on this news
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
Nexalin Technology has announced the advancement of its pivotal clinical trial for the HALO™ Clarity device, targeting moderate-to-severe insomnia, with patient enrollment expected to begin in Q2 2026. The trial, involving 160 participants, aims to support a De Novo Classification Request to the FDA, potentially establishing a new product category. Collaboration with Lindus Health is expected to enhance trial execution, while the company anticipates significant market opportunities in the insomnia treatment space.
Read more →NXL▲ +7.7%on this newsshared move
Nexalin Technology Advances Pivotal Clinical Trial of HALO Clarity Toward Q2 2026 Enrollment
Nexalin Technology, Inc. has announced the advancement of its pivotal clinical trial for the HALO Clarity device aimed at treating moderate-to-severe insomnia, with patient enrollment projected to begin in Q2 2026. This randomized and triple-blinded study is designed to support a De Novo FDA submission, potentially establishing a new product category for the HALO Clarity device. Nexalin's collaboration with Lindus Health aims to ensure rigorous trial execution and supports broader goals in insomnia treatment. Previous peer-reviewed data indicates positive treatment outcomes, bolstering the clinical case for this innovative approach to mental health.
Read more →NXL▲ +18.4%on this newsshared move
Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China
Nexalin Technology, Inc. has announced the successful completion of important meetings in the U.S. and China to advance its clinical strategy for Alzheimer's disease treatment. These discussions included a productive interaction with the FDA, which provided guidance on clinical trials. As a result, Nexalin is set to amend its Q-Submission application in Q2 2026. The collaboration with Professor Yi Tang in China brings valuable clinical insights which will inform Nexalin's approach to addressing cognitive decline in Alzheimer's patients.
Read more →NXLJoin Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
Nexalin Technology, Inc. will host an investor webinar on April 21, 2026, featuring CEO Mark White. The session will cover Nexalin's unique approach to mental healthcare using its Deep Intracranial Frequency Stimulation (DIFS) technology, along with updates on its product portfolio and regulatory advancements. A Q&A session will follow the presentation.
Read more →NXL▲ +8.6%on this news· ran to +23% by day 3shared move
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
Nexalin Technology, Inc. announced a peer-reviewed study published in BMC Psychiatry, demonstrating that its DIFS™ technology significantly reduced self-injury behaviors and depressive symptoms in female adolescents. The study involved six patients who underwent 21 days of stimulation, showing lasting improvements and changes in brain connectivity. The findings support the potential of DIFS as a non-invasive treatment for mental health disorders.
Read more →About Nexalin Technology, Inc.
Headquarters1776 YORKTOWN, HOUSTON, TX, 77056
BIOPHARMAWATCH ELITE PLUS
Trade the next NXL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime